COMMUNIQUÉS West-GlobeNewswire
-
iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings
12/10/2026 -
Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026
12/10/2026 -
Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery
12/10/2026 -
Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026
12/10/2026 -
STERIS Expands Healthcare Consumables Offering with Definitive Agreement to Acquire Xodus Medical, a Specialty Surgical Products Business Focused on Patient and OR Staff Safety
12/10/2026 -
Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-C
12/10/2026 -
Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia
12/10/2026 -
Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026
12/10/2026 -
NEXGEL Announces 1-for-20 Reverse Stock Split Effectiveness
12/10/2026 -
Kraig Labs Races to Scale Production as Billion-Dollar High-Performance Materials Market Starved for Scalable Supply Beckons
12/10/2026 -
SBC Medical to Present at Cantor Fitzgerald Hong Kong’s Inaugural Asia Longevity Forum
12/10/2026 -
Concept Life Sciences Appoints Dr Adrijana Vinter as Chief Executive Officer
12/10/2026 -
Transactions under Novonesis’ share buyback program
12/10/2026 -
Gates Foundation and Wellcome Leap Commit $100 Million to Reduce Global Stillbirth Rates
12/10/2026 -
Aprocitentan efficacy data reinforce endothelin pathway blockade as a distinct therapeutic approach across the cardiometabolic disease spectrum including obesity
12/10/2026 -
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Granted FDA Fast Track Designation for First-Line Advanced or Metastatic Biliary Tract Cancer
12/10/2026 -
InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China
12/10/2026 -
Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records
11/10/2026 -
First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026
11/10/2026
Pages